Glenmark Pharmaceuticals Ltd share price
Glenmark Pharmaceuticals Ltd (GLENMARK) is a stock listed on India's exchanges (NSE & BSE). It is commonly tracked under the Pharma theme. On Traddx you can view its live price, interactive candlestick charts with 20/50/200-day moving averages and golden/death-cross detection, quarterly results, analyst price targets, peer comparison, and the smart-money signal — which star investors hold it and who is buying it on today's bulk/block deals tape.
Glenmark Pharmaceuticals Limited value chain — customers, suppliers & competitors
Glenmark Pharmaceuticals is a research-led global pharmaceutical company that manufactures and sells generic drugs, specialty medicines, and over-the-counter (OTC) products across more than 80 countries, sitting between bulk chemical suppliers and end-market patients/retailers.
🛒 Customers — who buys from Glenmark Pharmaceuticals Limited
- Global Retail Pharmacies and Distributors — generic and OTC formulations (e.g., Adapalene Gel)
⛓️ Suppliers — raw materials & inputs
- Active Pharmaceutical Ingredients (API) Suppliers — raw chemicals and chemical intermediates
⚔️ Competitors — other sellers
- Lupin Limited — Competes directly in global generic formulations and US market share; Lupin is similar in scale.
- Alkem Laboratories — Competes strongly in the domestic formulations market; Alkem has a robust Indian footprint.
- IPCA Laboratories — Competes in domestic and international branded generics and API segments.
🔀 Other suppliers to its customers
- Dr. Reddy's Laboratories — Another major generic supplier to US and global retail pharmacies.
- Sun Pharmaceutical Industries — Largest Indian pharma player supplying overlapping generic portfolios.
🤝 Peers that share its suppliers
- Cipla Limited — Sources similar chemical intermediates and APIs from overlapping global vendor networks.
- Aurobindo Pharma — Shares similar raw material and chemical supplier ecosystems for generic manufacturing.
This value-chain map is AI-researched from public sources; company links and any figures are estimates, not official company disclosures. Not investment advice.